DE60023673D1 - Dna-impfung zur behandlung von autoimmunerkrankungen - Google Patents

Dna-impfung zur behandlung von autoimmunerkrankungen

Info

Publication number
DE60023673D1
DE60023673D1 DE60023673T DE60023673T DE60023673D1 DE 60023673 D1 DE60023673 D1 DE 60023673D1 DE 60023673 T DE60023673 T DE 60023673T DE 60023673 T DE60023673 T DE 60023673T DE 60023673 D1 DE60023673 D1 DE 60023673D1
Authority
DE
Germany
Prior art keywords
treatment
autoimmune diseases
dna vaccination
vaccination
recipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60023673T
Other languages
English (en)
Other versions
DE60023673T2 (de
Inventor
Lawrence Steinman
Pedro Jose Ruiz
Hideki Garren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of DE60023673D1 publication Critical patent/DE60023673D1/de
Application granted granted Critical
Publication of DE60023673T2 publication Critical patent/DE60023673T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE60023673T 1999-03-12 2000-03-10 Dna-impfung zur behandlung von autoimmunerkrankungen Expired - Lifetime DE60023673T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26759099A 1999-03-12 1999-03-12
US267590 1999-03-12
PCT/US2000/006233 WO2000053019A1 (en) 1999-03-12 2000-03-10 Dna vaccination for treatment of autoimmune disease

Publications (2)

Publication Number Publication Date
DE60023673D1 true DE60023673D1 (de) 2005-12-08
DE60023673T2 DE60023673T2 (de) 2006-07-20

Family

ID=23019424

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60043624T Expired - Lifetime DE60043624D1 (de) 1999-03-12 2000-03-10 DNA-Impfung zur Behandlung von Autoimmunerkrankungen
DE60023673T Expired - Lifetime DE60023673T2 (de) 1999-03-12 2000-03-10 Dna-impfung zur behandlung von autoimmunerkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60043624T Expired - Lifetime DE60043624D1 (de) 1999-03-12 2000-03-10 DNA-Impfung zur Behandlung von Autoimmunerkrankungen

Country Status (9)

Country Link
EP (3) EP2177228A1 (de)
JP (1) JP2003508346A (de)
AT (2) ATE308244T1 (de)
CA (1) CA2363269C (de)
DE (2) DE60043624D1 (de)
DK (2) DK1621208T3 (de)
ES (2) ES2251974T3 (de)
PT (1) PT1621208E (de)
WO (1) WO2000053019A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2301552A1 (de) * 2001-11-21 2011-03-30 The Board Of Trustees Of The Leland Stanford Junior University Polynukleotidtherapie
JP2010511381A (ja) 2006-11-30 2010-04-15 メディポスト・カンパニー・リミテッド 神経前駆細胞又は神経幹細胞の神経細胞への分化及び増殖の誘導方法、分化及び増殖誘導用組成物、及び薬学的製剤
CN100571786C (zh) * 2007-03-26 2009-12-23 中国农业大学 一种预防和/或治疗自身免疫疾病的疫苗
KR20100054711A (ko) 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
SE535625C2 (sv) 2010-10-28 2012-10-16 Toleranzia Ab Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
KR101615161B1 (ko) 2011-02-02 2016-04-25 메디포스트(주) 신경질환의 예방 또는 치료를 위한 icam-1의 용도
GB201112806D0 (en) * 2011-07-26 2011-09-07 Bauer Johann Use of epitopes inducing specific tolerance for the prevention of tissue rejection
WO2013160865A1 (en) 2012-04-26 2013-10-31 Toleranzia Ab Immunotolerizing fusion proteins for treatment of multiple sclerosis
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
US10898590B2 (en) 2015-09-21 2021-01-26 Kolon Life Science, Inc. Method for delivery of biological molecule to nervous tissue
KR20170034701A (ko) 2015-09-21 2017-03-29 코오롱생명과학 주식회사 통증 치료용 조성물
WO2023086969A2 (en) * 2021-11-12 2023-05-19 Ichor Medical Systems Inc. Treatment methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891435A (en) 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US6274136B1 (en) * 1996-05-29 2001-08-14 University Of Southern California Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
AU3225097A (en) * 1996-06-03 1998-01-05 Auragen, Inc. Immunotherapy for autoimmune disease

Also Published As

Publication number Publication date
EP2177228A1 (de) 2010-04-21
WO2000053019A1 (en) 2000-09-14
EP1168923A4 (de) 2002-06-26
EP1621208B1 (de) 2009-12-30
EP1168923B1 (de) 2005-11-02
PT1621208E (pt) 2010-04-07
JP2003508346A (ja) 2003-03-04
ES2338890T3 (es) 2010-05-13
DK1168923T3 (da) 2006-03-20
CA2363269C (en) 2012-06-12
ATE308244T1 (de) 2005-11-15
DE60043624D1 (de) 2010-02-11
ATE453404T1 (de) 2010-01-15
EP1168923A1 (de) 2002-01-09
DE60023673T2 (de) 2006-07-20
DK1621208T3 (da) 2010-05-10
CA2363269A1 (en) 2000-09-14
ES2251974T3 (es) 2006-05-16
EP1621208A1 (de) 2006-02-01

Similar Documents

Publication Publication Date Title
DE60023673D1 (de) Dna-impfung zur behandlung von autoimmunerkrankungen
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
HK1078777A1 (en) Modified vaccinia virus ankara for the vaccination of neonates
IL92382A0 (en) Immunotherapy involving cd28 stimulation
FI932678A0 (fi) Pao alfavirus baserande DNA expressionssystem
DE60045034D1 (de) Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen
BR0012748A (pt) Análogo super-ativo do hormÈnio de lberação do hormõnio do crescimento porcino
ATE368378T1 (de) Dns-impfung zur einleitung einer suppressiven t- zell-antwort
ATE181501T1 (de) Verwendung von l-deprenyl zur hemmung des alterniedergangs des immunsystems in säugetieren
DE60334725D1 (de) N vitro zur behandlung von tumoren
HUP9900681A2 (hu) TH1/TH2-citokinexpresszió modulálása Ribavirinnel és Ribavirin-analógokkal, aktivált T-limfocitákban
AR026059A1 (es) Virus de plantas modificadas y metodos para su uso
Habibi et al. Cytokine gene expression in healing and non‐healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi‐quantitative RT–PCR
ATE71662T1 (de) Einen menschlichen granulozytkoloniereizfaktor fuer die behandlung von leukopenien enthaltende pharmazeutische zubereitung.
DK1699480T3 (da) Allogent terapeutisk tumormiddel
ATE348876T1 (de) Verfahren zur vermehrung von natürlichen killerzellen
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
ATE386543T1 (de) Verwendung polyklonaler anti-il-2 antikörper zur behandlung von insulin-abhängigen diabetes mellitus und lupus erythematosus
YU40796A (sh) Preparati i postupci za tretiranje obolenja koja izazivaju t ćelije
DE60130775D1 (de) Stimulierung der neutrophilfunktion zur behandlung von entzündlichen darmerkrankungen
DE69528473T2 (de) Verwendung von hepatozyten-wachstumsfaktor zur induzierung der proliferation und differenzierung von hämatopoietischen zellen
DK0538330T3 (da) Beta-Alethin-anvendelse til celledyrkning og terapi
PH23658A (en) Improved method of treating tumors with autologous lymphokine activated killer,interleukin-2 and an ornithine decarboxylase inhibitor
PT1016414E (pt) Hormona de crescimento humano para estimular a hematopoiese e a reconstituicao imnologica apos transplante de celulas estaminais hematopoieticas em humanos
ATE446767T1 (de) Gm-csf zur behandlung von morbus crohn

Legal Events

Date Code Title Description
8364 No opposition during term of opposition